Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Paying for CAR-T Therapy Amidst Limited Health System Resources.

Campbell JD, Whittington MD.

J Clin Oncol. 2019 Jun 3:JCO1901113. doi: 10.1200/JCO.19.01113. [Epub ahead of print] No abstract available.

PMID:
31157580
2.

Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.

Xiao W, Salem D, McCoy CS, Lee D, Shah NN, Stetler-Stevenson M, Yuan CM.

Cytometry B Clin Cytom. 2018 May;94(3):434-443. doi: 10.1002/cyto.b.21591. Epub 2017 Oct 31.

3.

Standardizing CAR-T therapy: Getting it scaled up.

Dai X, Mei Y, Cai D, Han W.

Biotechnol Adv. 2019 Jan - Feb;37(1):239-245. doi: 10.1016/j.biotechadv.2018.12.002. Epub 2018 Dec 10. Review.

PMID:
30543841
4.

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.

Grigor EJM, Fergusson DA, Haggar F, Kekre N, Atkins H, Shorr R, Holt RA, Hutton B, Ramsay T, Seftel M, Jonker D, Daugaard M, Thavorn K, Presseau J, Lalu MM.

BMJ Open. 2017 Dec 29;7(12):e019321. doi: 10.1136/bmjopen-2017-019321.

5.

Target selection of CAR T cell therapy in accordance with the TME for solid tumors.

Liu B, Yan L, Zhou M.

Am J Cancer Res. 2019 Feb 1;9(2):228-241. eCollection 2019. Review.

6.

CAR T-cell Therapy: A New Era in Cancer Immunotherapy.

Miliotou AN, Papadopoulou LC.

Curr Pharm Biotechnol. 2018;19(1):5-18. doi: 10.2174/1389201019666180418095526. Review.

PMID:
29667553
7.

Chimeric antigen receptor-engineered T-cell therapy for liver cancer.

Chen Y, E CY, Gong ZW, Liu S, Wang ZX, Yang YS, Zhang XW.

Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24. Review.

PMID:
29861325
8.

Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.

Gauthier J, Yakoub-Agha I.

Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003. Review.

PMID:
28988742
9.

Adult Survivorship: Considerations Following CAR T-Cell Therapy.

Buitrago J, Adkins S, Hawkins M, Iyamu K, Oort T.

Clin J Oncol Nurs. 2019 Apr 1;23(2):42-48. doi: 10.1188/19.CJON.S1.42-48.

PMID:
30880816
10.

Toxicities of chimeric antigen receptor T cells: recognition and management.

Brudno JN, Kochenderfer JN.

Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20. Review.

11.

Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.

Maus MV, Levine BL.

Oncologist. 2016 May;21(5):608-17. doi: 10.1634/theoncologist.2015-0421. Epub 2016 Mar 23. Review.

12.

Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.

Kiani J, Naderi M, Torabi-Rahvar M, Ranjbar A, Aghayan HR, Janzamin E, Ahmadbeigi N.

Arch Iran Med. 2019 Jan 1;22(1):7-10.

13.

Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

Sarkar RR, Gloude NJ, Schiff D, Murphy JD.

J Natl Cancer Inst. 2018 Dec 14. doi: 10.1093/jnci/djy193. [Epub ahead of print]

PMID:
30551196
14.

Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies.

Jung IY, Lee J.

Mol Cells. 2018 Aug 31;41(8):717-723. doi: 10.14348/molcells.2018.0242. Epub 2018 Aug 14. Review.

15.

Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.

Magee MS, Snook AE.

Discov Med. 2014 Nov;18(100):265-71. Review.

16.

Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model.

Ando Y, Siegler EL, Ta HP, Cinay GE, Zhou H, Gorrell KA, Au H, Jarvis BM, Wang P, Shen K.

Adv Healthc Mater. 2019 Mar;8(5):e1900001. doi: 10.1002/adhm.201900001. Epub 2019 Feb 8.

17.

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma.

Petersen CT, Krenciute G.

Front Oncol. 2019 Feb 26;9:69. doi: 10.3389/fonc.2019.00069. eCollection 2019. Review.

18.

Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors.

Xu J, Wang Y, Shi J, Liu J, Li Q, Chen L.

Oncol Lett. 2018 Aug;16(2):2063-2070. doi: 10.3892/ol.2018.8946. Epub 2018 Jun 11. Review.

19.

CAR-T immunotherapy: how will it change treatment for acute lymphoblastic leukemia and beyond?

Capitini CM.

Expert Opin Orphan Drugs. 2018;6(10):563-566. doi: 10.1080/21678707.2018.1529562. Epub 2018 Oct 8.

PMID:
30775189
20.

Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.

Siegler EL, Wang P.

Hum Gene Ther. 2018 May;29(5):534-546. doi: 10.1089/hum.2017.243. Epub 2018 Mar 14. Review.

PMID:
29390873

Supplemental Content

Support Center